A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas-Reference-Cited by-同舟云学术

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Published:2017-03-07 Issue:10 Volume:58 Page:2310-2318
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sborov Douglas W.¹,Canella Alessandro²,Hade Erinn M.³,Mo Xiaokui³,Khountham Soun²,Wang Jiang²,Ni Wenjun⁴,Poi Ming²⁴,Coss Christopher²⁴,Liu Zhongfa⁴,Phelps Mitch A.²⁴,Mortazavi Amir⁵,Andritsos Leslie⁶,Baiocchi Robert A.⁶,Christian Beth A.⁶,Benson Don M.⁶,Flynn Joseph⁶,Porcu Pierluigi⁶,Byrd John C.⁶,Pichiorri Flavia⁷,Hofmeister Craig C.⁶

Affiliation:

1. Division of Hematology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA;

2. Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;

3. Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA;

4. Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;

5. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

6. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

7. Comprehensive Cancer Center, City of Hope, Duarte, CA, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1298751

Reference36 articles.

1. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

2. Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

3. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

4. Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

5. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo;International Journal of Molecular Sciences;2024-07-18

2. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors;Frontiers in Immunology;2023-11-23

3. 2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines;Bioorganic & Medicinal Chemistry;2023-10

4. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL);Clinical Epigenetics;2023-08-02

5. Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy;Scientific Reports;2023-06-26